Trial Profile
A National Phase I Study of Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Isotretinoin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Nov 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 03 Oct 2022 Planned End Date changed from 1 Dec 2022 to 1 Aug 2023.